A novel two-drug strategy has shown significant promise in halting the growth of pancreatic cancer in preclinical studies, offering a new path to treat one of oncology's most lethal diseases. The approach cleverly repurposes existing medications to indirectly cripple the tumor's growth mechanism, bypassing a historically difficult-to-target genetic driver.
The research focuses on pancreatic ductal adenocarcinoma, an aggressive cancer often detected late and resistant to treatment. In most cases, a mutation in the KRAS gene drives uncontrolled cell division. Directly targeting KRAS has proven challenging. Instead, scientists looked downstream, at a cellular "brake" protein called RB1. In pancreatic cancer, this brake is disabled by a protein system involving CDK4/6. The researchers used CDK4/6 inhibitor drugs, already approved for breast cancer, to restore RB1's function. This successfully stopped cancer cells from dividing, forcing them into a dormant state known as senescence.
However, these senescent cells remained alive and could reactivate. The team discovered that blocking RB1 triggered a survival signal through a receptor called EGFR. To achieve cell death, they combined the CDK4/6 inhibitor with an EGFR blocker like gefitinib or cetuximab. This sequential combination first induced senescence and then selectively eliminated those dormant cells, a process called senolysis. In models using mice and human tumor samples, this dual approach caused significant cancer cell death.
Importantly, the treatment did not appear to cause harmful senescence in healthy tissues in advanced mouse models, suggesting a potential safe therapeutic window. The researchers stress the sequence is critical: the senescence-inducing drug must be administered first, followed by the EGFR inhibitor to clear the dormant cells.
With the strategy relying on drugs already in medical use, the path to human clinical trials could be accelerated. If validated in patients, this indirect method of targeting pancreatic cancer's core weakness could eventually improve outcomes for a disease where new effective treatments are urgently needed.